AAFP & AFP curated list of resources.
The severity of the Covid-19 pandemic has led to the use of extreme control measures which has halted the spread, but at enormous socioeconomic cost. We set out to explore whether a model that includes 'superspreader' could explain aspects of mitigation strategies that explain the dramatic effect. Methods: We developed an age structured agent-based model that includes persons who spread the dis...
There is no clear definition for the term ‘super-spreader’ or ‘super-spreading event’. The World Health Organization refers to a super-spreader as a patient (or an event) that may transmit infection to a larger number of individuals than is usual by one individual (or event). In the severe acute respiratory syndrome (SARS) situation, a super-spreading event was defined as the transmission of SA...
While the “right” time to open the economy is hotly debated, many states have made the decision that it is time to get back to business. That means that businesses will be opening while there is still a continuing risk of COVID-19 exposure. As long as the risk of exposure remains, businesses face potential liability when they allow customers, vendors, and other parties to enter their premises...
Pandemic fears have created interest in metallic products touting antimicrobial properties. But experts have doubts about the copper craze.
A recent clinical study that indicates copper is far better than other common materials at preventing the spread of infectious diseases has caught the public’s attention amid the ongoing coronavirus pandemic.
consider stopping elective procedures amid the COVID-19 outbreak. On March 18, the Centers for Medicare & Medicaid Services (CMS) also released guidance to limit "non-essential adult elective surgery and medical and surgical procedures, including all dental procedures." The guidance additionally notes that while "decisions remain the responsibility of local healthcare delivery systems...and tho...
The situation involving the COVID-19 pandemic continues to evolve. There is recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding1,2 posing potential risks during endoscopy and colonoscopy to other patients, endoscopy personnel and ourselves. We provide below important information as well as recommendations to consider in your insti...
To aggressively address COVID-19, CMS recognizes that conservation of critical healthcare resources is essential, in addition to limiting exposure of patients and staff to the virus that causes COVID-19. CMS also recognizes the importance of reducing burdens on the existing health system and maintaining services while keeping patients and providers safe. CMS, in collaboration with medical s...
This educational primer is meant to introduce new internal medicine interns and other providers to some of the basic concepts of managing floor patients suspected or confirmed of having COVID-19.
In response to the COVID-19 pandemic, Copper Development Association (CDA) developed the following position statement to address an influx of inquiries from the media and external stakeholders.
American Heart Association
AHA High Blood Pressure Toolkit
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently give...
The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the COVID-19. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
The New England Journal of Medicine;
Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.
This action seeks immediate court intervention to stop Defendant Landmark Hospital from concealing and mishandling a COVID-19 outbreak in their facility, and to prevent Defendant Landmark from receiving patients into their facility or discharging or transferring patients out of their facility.
The U.S. Food and Drug Administration is issuing warning letters to firms for selling fraudulent products with claims to prevent, treat, mitigate, diagnose or cure coronavirus disease 2019 (COVID-19). We are actively monitoring for any firms marketing products with fraudulent COVID-19 prevention and treatment claims. The FDA is exercising its authority to protect consumers from firms selling un...
The swiftly moving novel coronavirus continues its relentless spread around the world, upending life as we know it and creating a breeding ground for misinformation. Some rumors are harmless, while others can be dangerous, stoking fear and threatening health. Here, we separate true from false, based on the best science and expertise available.
Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colch...
In contrast, we consider that colchicine can be a good therapeutic option because of several effects in the immunology system involved in SARS-CoV-2 infection and in the acute respiratory distress syndrome (ARDS). Colchicine has effects on the chemotaxis of inflammatory cells such as neutrophils and monocytes and on the intracellular transportation of vesicles such as endosomes and exosomes.
The International Journal of Clinical Practice;
The COVID‐19 pandemic is caused by infection with the SARS‐CoV‐2 virus. The major mutation detected to date in the SARS‐CoV‐2 viral envelope spike protein, which is responsible for virus attachment to the host and is also the main target for host antibodies, is a mutation of an aspartate (D) at position 614 found frequently in Chinese strains to a glycine (G). We sought to infer health impact o...
https://www.scripps.edu/_files/pdfs/news-and-events/The D614G mutation in the SARS-CoV-2 spike protein reduces S1.pdf
SARS coronavirus 2 (SARS-CoV-2) isolates encoding a D614G mutation in the viral spike (S) protein predominate over time in locales where it is found, implying that this change enhances viral transmission. We therefore compared the functional properties of the S proteins with aspartic acid (SD614) and glycine (SG614) at residue 614. We observed that retroviruses pseudotyped with SG614 infect...
A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the United States significantly increases the virus’ ability to infect cells, lab experiments performed at Scripps Research show.
Geriatrician Sharon Inouye on the need to combat delirium in COVID-19 patients
A mutation affecting the virus's spike protein changed amino acid 614 from “D” (aspartic acid) to “G” (glycine). Research suggests that this small change — which affects three identical amino acid chains — might make the spike protein more effective, enhancing the virus’s infectiousness.
Geneticists said more evidence is needed to determine if a common genetic variation of the virus spreads more easily between people.
We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020.
To a startling degree, many coronavirus patients are reporting similar experiences. Called hospital delirium, the phenomenon has previously been seen mostly in a subset of older patients, some of whom already had dementia, and in recent years, hospitals adopted measures to reduce it.
Delirium incidence, duration and severity in patients admitted to the intensive care unit (ICU) due to COVID-19 is not known.
Journal of Movement Disorders;
We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9)...
Frontiers in Neurology;
Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).
Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...
Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.